Compare · LLY vs MTVA
LLY vs MTVA
Side-by-side comparison of Eli Lilly and Company (LLY) and MetaVia Inc. (MTVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and MTVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 105725.1x MTVA ($10.1M).
- Over the past year, LLY is up 44.1% and MTVA is down 74.2% - LLY leads by 118.3 points.
- Both names hit the wire about 19 times in the past 4 weeks.
- LLY has more recent analyst coverage (25 ratings vs 2 for MTVA).
- Company
- Eli Lilly and Company
- MetaVia Inc.
- Price
- $1165.28+2.55%
- $2.13+10.94%
- Market cap
- $1.07T
- $10.1M
- 1M return
- +17.69%
- +119.59%
- 1Y return
- +44.11%
- -74.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 19
- 19
- Recent ratings
- 25
- 2
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
- FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
Latest MTVA
- Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream
- Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream
- BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
- Director Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)
- Director Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)
- Director Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)
- Director Groves Jason L was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)
- Director Koven Andrew I was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)
- Director Glickman Mark A was granted 17,186 shares, increasing direct ownership by 499% to 20,629 units (SEC Form 4)
- SEC Form S-8 filed by MetaVia Inc.